Neoleukin Therapeutics, Inc., a pioneering biotechnology firm based in the United States, focuses on the development of innovative immunotherapies for cancer and autoimmune diseases. Founded in 2018, the company has rapidly advanced its proprietary Neoleukin platform, which leverages computational design to create novel protein therapeutics. Headquartered in Seattle, Washington, Neoleukin operates primarily within the biopharmaceutical industry, aiming to revolutionise treatment options through its unique approach to protein engineering. The company’s lead product candidates, designed to mimic the activity of naturally occurring cytokines, stand out for their potential to enhance immune responses while minimising side effects. With a commitment to scientific excellence, Neoleukin Therapeutics has positioned itself as a notable player in the immunotherapy landscape, attracting significant attention for its innovative solutions and promising clinical developments.
We don't have data for Neoleukin Therapeutics, Inc., but we can show you information about their parent organization instead.
View parent company